亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        Sudden cardiac death in a case of Crohn's disease with COVID-19: A case report

        2022-07-02 05:53:02NeerajKumarSubhajitGhoshAbhyudayKumarSanjeevKumarPremKumar
        Journal of Acute Disease 2022年3期
        關(guān)鍵詞:腔室流線擋板

        Neeraj Kumar, Subhajit Ghosh, Abhyuday Kumar, Sanjeev Kumar, Prem Kumar

        Departments of 1Trauma & Emergency, 2Anaesthesiology, 3CTVS, and 4Radiology, All India Institute of Medical Sciences, Patna, India

        ABSTRACT

        KEYWORDS: COVID-19; Sudden cardiac death; Chron’s disease

        1. Introduction

        Inflammatory bowel diseases (IBD) like Crohn’s disease (CD)and ulcerative colitis (UC) are chronic inflammatory diseases of the intestines that may present with many venous vascular comorbidities such as deep venous thrombosis or portal vein thrombosis. These chronic systemic inflammations may lead to endothelial dysfunction and platelet aggregation and serve as a precursor to the development of atherosclerosis and coronary artery disease (CAD)[1]. As per the literature, SARS-CoV-2 can lead to unfavorable outcomes in elderly patients with comorbidities, for example, cardiovascular dysfunction[2]. Sudden cardiac death (SCD) has emerged as one of the most challenging concerns amid the COVID-19 pandemic[3].Although the direct causal association between SCD and COVID-19 remains unproven, but some published data may suggest a plausible association.

        2. Case report

        Departmental Ethics Committee, All India Institute of Medical Sciences Patna, Bihar, India, approved the reporting of this case, and the informed consent was obtained from the patient’s relatives.

        A 75-year COVID-19 patient was admitted to our intensive care unit because of the shortness of breath for the last 2 days. He was a known case of Crohn’s disease and hypothyroidism and was on tablet mesalamine 1 g and tablet levothyroxine 25 μg daily. He had stable vitals and maintained saturation on the non-rebreathing mask with a reservoir bag. As per our institutional COVID-19 management protocol, remdesivir, antibiotics, steroids, low molecular weight heparin, tablet zinc, tablet vitamin C, and other supportive treatment were started. Because of increased inflammatory markers, itolizumab was given to the patient on the 2nd day. Artery blood gas was within acceptable limits with a PaO2/FiO2ratio of 121. The normal arterial blood gases were PH of 7.36, PaO2of 78 mmHg, PaCO2of 33 mmHg, HCO3of 21 mmol/L. The chest X-Ray finding was typically suggestive of COVID-19 with patchy areas of ground-glass opacity in the middle and lower zones in the right and middle zone in the left,with normal costophrenic angle (Figure 1). On the 3rd day, oxygen requirement was further increased, and oxygen saturation dropped below 90% with a respiratory rate of 38-40 rates per minute. He was put on a high-flow nasal oxygenation machine with a FiO2of 0.8 and with a flow rate of 5 L/ min. On the 4th day, the patient’s condition was improved, and oxygen saturation was maintained between 95%-97% on transnasal high flow oxygen therapy with FiO2of 0.6 and at a flow rate of 5 L/min. Routine investigations on days three and four were almost normal except for the inflammatory markers which were raised (Table 1). A day-by-day clinical progression is shown in Table 2.

        Figure 1. The chest X-ray (AP-view) of a 75-year-old man with COVID-19.White arrows show extensive opacities in bilateral lungs.

        Table 1. Day wise laboratory and inflammatory markers values.

        Table 2. Clinical course of the patient during ICU stay.

        On the 5th day, the patient complained of sudden chest pain with respiratory distress. A 12-lead electrocardiograph was taken which showed no significant ST-segment change, and trop T was negative. 2-D bedside echocardiography did not show any evidence of pulmonary embolism with normal chamber size and normal left ventricular ejection fraction. But the patient immediately went into bradycardia and followed by asystole. Cardiopulmonary resuscitation was initiated promptly per Advanced Cardiac Life Support protocol; all reversible causes, including tension pneumothorax, cardiac tamponade, and electrolyte/metabolic disturbances were ruled out. However, the patient was not revived and was declared dead.

        3. Discussion

        The mechanism of SCD in COVID-19 can be multifactorial. However,it remains difficult to ascertain the most common mechanism involved due to a lack of data. Both tachyarrhythmia and bradyarrhythmia have been reported in COVID-19. Fatal arrhythmias in COVID-19 may also result from hypoxia, cardiac dysfunction, severe systemic inflammatory state, electrolyte derangements, intravascular volume imbalances,and drug side effects[4]. Guo et al.[5] suggested life-threatening arrhythmias have been variably reported from 10% to 16% of patients hospitalized for severe COVID-19, more commonly in the setting of elevated troponin indicating myocardial injury. Some of the proposed causes of sudden cardiac death in COVID-19 are acute myocarditis(stress-induced cardiomyopathy), acute coronary syndrome, hypoxia,pulmonary thromboembolism, coronary thrombosis, stroke, cardiac tamponade, electrolyte imbalance, underlying channelopathies, and drug-induced arrhythmias. Direct arrhythmogenesis by COVID-19 cytokines has a direct electrophysiological effect on the myocardium,IL-6, tumor necrosis factor-α, and IL-1 can prolong ventricular action potential duration. These cytokines may induce cardiac sympathetic system hyperactivation, which can trigger life-threatening arrhythmic events in patients with long QT[6]. In our case, QT/QTc was 348/452 ms, so the possibility of any QTc prolongation was ruled out. The deep vein thrombosis and pulmonary embolism was also ruled out because of normal echocardiography findings with normal d-dimer and prothrombin time.

        Studies have found that IBDs are associated with an increased risk of CAD, cerebrovascular diseases, and peripheral arterial diseases[7]. High levels of circulating cytokines and C-reactive protein are characteristic of IBD, and it is therefore expected to contribute to endothelial dysfunction and atherogenesis. The possible causes of increased cardiovascular events in patients with IBD can be raised inflammatory markers, endothelial dysfunction, hypercoagulability, and release of endotoxins and lipoproteins[7].

        The drug mesalazine (5-ASA) is efficacious in active Crohn’s and ulcerative colitis and are generally regarded as a safe and well-tolerated medication[8]. Cardiac hypersensitivity to 5-ASA therapy leading to myocarditis has been reported in some case studies, and the first reported death from myocarditis associated with mesalazine use was in 1990[9]. In documented literature, hypersensitivity appears to be an idiosyncratic reaction rather than dose-dependent due to its occurrence in patients on very low amounts of mesalazine such as 0.5 g a day[10].

        In our case, sudden cardiac death was possibly due to cardiovascular complications caused by cytokine storm syndrome (raised inflammatory markers) and idiosyncratic reaction with mesalazine use. Our patient had a high-risk factor for cardiovascular complications due to COVID-19, IBD, and mesalazine. Mesalazine is very safe and efficacious in the management of inflammatory bowel disease but we should be aware of its serious and potentially life-threatening complications that may occur especially if it has to be used in COVID-19 infected patients.

        To sum up, immunosuppressants in hospitalized COVID-19 patients should be continued with caution. There should be a baseline electrocardiograph to check QTc interval and look for other risk markers of tachy or bradyarrhythmias. Metabolic parameters including electrolytes, fluid volume, and acidosis should be actively sought and treated at the earliest possible, especially in the ICU. Every patient deserves risk stratification based on his/her clinical background with complete available information.

        Conflict of interest statement

        圖3無擋板結(jié)構(gòu),中心區(qū)域因氣流進(jìn)入時(shí)無阻擋,而以較大流速直接沖入腔室,從而產(chǎn)生流場擾動(dòng),且中心區(qū)域孔密度較高,邊緣孔密度小,邊緣流線較稀疏;

        The authors report no conflict of interest.

        Funding

        This study received no extramural founding.

        Authors’ contributions

        N.K.: Manuscript writing, proofreading, and final drafting; S.G.:Case management; manuscript writing A.K.: Final drafting; S.K.:Proofreading; P.K.: Proofreading.

        猜你喜歡
        腔室流線擋板
        平拋運(yùn)動(dòng)中的“擋板”問題探究
        急冷增濕塔以及含硫廢棄物處理系統(tǒng)
        能源化工(2022年1期)2023-01-14 05:59:21
        燃燒器二次風(fēng)擋板開度對爐內(nèi)燃燒特性的影響
        類橢圓型采油螺桿泵舉升性能分析*
        幾何映射
        壓電傳感器
        傳感器世界(2019年3期)2019-02-17 13:07:26
        任意夾角交叉封閉邊界內(nèi)平面流線計(jì)算及應(yīng)用
        大型綜合交通樞紐流線組織設(shè)計(jì)
        CO2混相驅(qū)五點(diǎn)井網(wǎng)流線模擬
        玩意兒
        亚洲av第一页国产精品| 中文字幕一区二区综合| 久久久精品国产免大香伊| 亚洲黄色av一区二区三区| 国产不卡精品一区二区三区| 欧美牲交a欧美牲交aⅴ免费真| 亚洲精品无码久久毛片| 亚洲日韩国产精品不卡一区在线| 狼人精品剧情av在线观看| 无码aⅴ精品一区二区三区浪潮| 曰本极品少妇videossexhd| 日韩中文无线码在线视频观看| 女优免费中文字幕在线| 亚洲精品国产熟女久久久| 户外精品一区二区三区| 国产av无码专区亚洲av毛网站| 国产精品密播放国产免费看| 无人视频在线播放在线观看免费| 少妇精品偷拍高潮少妇在线观看| 日韩内射美女片在线观看网站| 中文字幕一区二区人妻| a午夜国产一级黄片| 白白色最新福利视频二| 亚洲无线码一区二区三区| 中文幕无线码中文字蜜桃| 亚洲二区三区在线播放| 久久精品亚洲精品国产区| 扒开腿狂躁女人爽出白浆| 中文字幕av在线一二三区| 亚洲视频中文字幕更新| 亚洲日本一区二区在线| 亚洲av无码国产精品永久一区| 无码欧亚熟妇人妻AV在线外遇 | 在线观看国产成人av片| 精品一区二区三区影片| 婷婷丁香开心五月综合| 人妻少妇精品中文字幕av| 国产精品三级一区二区按摩| 亚洲综合在线一区二区三区| 十八禁无遮挡99精品国产| 柠檬福利第一导航在线|